Discovery Could Help Understand Breast-Cancer Therapies

October 03, 1996

CHAMPAIGN, Ill. -- Breast-cancer researchers at the University of Illinois have identified four amino acids viewed as leading actors in the binding of estrogen and anti-estrogen hormones to receptor proteins in the female reproductive system.

The findings could prove to be crucial in efforts to understand how the receptors respond to drug therapies and how they become resistant to tamoxifen, which, for 20 years, has been the anti-estrogen agent most commonly used against breast cancer in the United States, said lead researcher Benita Katzenellenbogen, a professor of molecular and integrative physiology.

The research was published in the Aug. 16 issue of The Journal of Biological Chemistry. The authors were Katzenellenbogen, who on Oct. 18 will receive the 1996 Komen Scientific Distinction Award from the Susan G. Komen Breast Cancer Foundation in Dallas; her husband, John Katzenellenbogen, professor of chemistry; Kirk Ekena, postdoctoral researcher; and Karen E. Weis, research associate.

The estrogen receptor is a protein containing about 600 amino acids. It takes in estrogen, providing the transcription signal (the message system) for biological activity important in bone maintenance, especially for postmenopausal women, and for cardiovascular protection. But estrogen also increases the risk of breast cancer in some women.

"We've identified portions of the hormone-binding domain of this protein that appear to be critical sites for binding with the hormone," Benita Katzenellenbogen said. "We've shown that if one alters one of these four amino acids then one eliminates the ability of estrogen to bind, and as a consequence one also eliminates the ability of these receptors to act as transcriptional regulators."

The research, funded by the National Institutes of Health, was conducted using a molecular biological technique called alanine-scanning mutagenesis, in which a different form of amino acid is substituted one at a time into specific positions along the receptor protein.

Anti-estrogens bind to the same receptor as estrogens. In fighting breast cancer, tamoxifen blocks the binding of estrogen, enabling the drug to work against the growth of cancer cells while still having beneficial effects on the heart and bones. But tamoxifen also has weak estrogen-like activity that has been linked to cancer of the uterus. It also loses its effectiveness as cancer cells become resistant to it.

Benita Katzenellenbogen is now focusing on how the receptors interpret the difference between estrogen and anti-estrogen and, in turn, activate appropriate genes or growth factors along the biological pathway in the body. Her lab also has developed models of tamoxifen-resistant human cells in an attempt to understand how resistance develops.

"Understanding these pathways should provide insight that should help in drug development for therapies that are more tissue selective," she said. "These studies are of enormous importance for the effective, long-term treatment of breast cancer."
###




University of Illinois at Urbana-Champaign

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.